Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Sep 25:11:670-678.
doi: 10.1016/j.dadm.2019.08.004. eCollection 2019 Dec.

Using subjective cognitive decline to identify high global amyloid in community-based samples: A cross-cohort study

Affiliations

Using subjective cognitive decline to identify high global amyloid in community-based samples: A cross-cohort study

Rachel F Buckley et al. Alzheimers Dement (Amst). .

Abstract

Introduction: We aimed to examine the contribution of subjective cognitive decline (SCD) to reduce the number of β-amyloid (Aβ) positron emission tomography scans required for recruiting Aβ+ clinically normal individuals in clinical trials.

Methods: Three independent cohorts (890 clinically normal: 72 yrs ± 6.7; Female: 43.4%; SCD+: 24%; apolipoprotein E [APOE] ε4+: 28.5%; Aβ+: 32%) were used. SCD was dichotomized from one question. Using logistic regression, we classified Aβ+ using the SCD dichotomy, APOEε4, sex, and age.

Results: SCD increased odds of Aβ+ by 1.58 relative to non-SCD. Female APOEε4 carriers with SCD exhibited higher odds of Aβ+ (OR = 3.34), whereas male carriers with SCD showed a weaker, opposing effect (OR = 0.37). SCD endorsement reduces the number of Aβ positron emission tomography scans to recruit Aβ+ individuals by 13% and by 9% if APOEε4 status is known.

Conclusion: SCD helps to classify those with high Aβ, even beyond the substantial effect of APOE genotype. Collecting SCD is a feasible method for targeting recruitment for those likely on the AD trajectory.

Keywords: APOEε4; Alzheimer's disease; Amyloid; Subjective cognitive decline.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Probability of having high Aβ according to SCD endorsement and APOEε4 carrier status. Abbreviations: APOE, apolipoprotein E; SCD, subjective cognitive decline.
Fig. 2
Fig. 2
Probability of having high Aβ according to SCD endorsement and sex in (A) APOEε4 carriers and (B) noncarriers. Abbreviations: APOE, apolipoprotein E; SCD, subjective cognitive decline.

References

    1. Sperling R.A., Mormino E., Johnson K. The Evolution of Preclinical Alzheimer’s Disease: Implications for Prevention Trials. Neuron. 2014;84:608–622. - PMC - PubMed
    1. Sperling R.A., Rentz D.M., Johnson K.A., Karlawish J., Donohue M., Salmon D.P. The A4 Study: Stopping AD Before Symptoms Begin? Sci Translational Med. 2014;6:228fs13. - PMC - PubMed
    1. Rowe C.C., Ellis K., Rimajova M., Bourgeat P., Pike K.E., Jones G. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging. 2010;31:1275–1283. - PubMed
    1. Jansen W.J., Ossenkoppele R., Knol D.L., Tijms B.M., Scheltens P., Verhey F.R. Prevalence of cerebral amyloid pathology in persons without dementia: A meta-analysis. JAMA. 2015;313:1924–1938. - PMC - PubMed
    1. Mielke M.M., Wiste H.J., Weigand S.D., Knopman D.S., Lowe V.J., Roberts R.O. Indicators of amyloid burden in a population-based study of cognitively normal elderly. Neurology. 2012;79:1570–1577. - PMC - PubMed